The company also announced its expectations for 2026, projecting revenues to exceed $110 million with an Adjusted EBITDA margin of over 30%. This optimistic outlook is bolstered by the recent acquisition of HEMANGEOL, which is anticipated to be accretive to earnings in 2026. Eton's CEO, Sean Brynjelsen, expressed confidence in the company's growth trajectory, highlighting the successful launch of three major products in 2025 and the strong reception of DESMODA in its initial weeks on the market. The company plans to hold a conference call to discuss these results and future strategies, further engaging with investors and stakeholders.
2026-03-21 13:35:56
Eton Pharmaceuticals Reports 83% Growth in Q4 2025 Sales, Expects 2026 Revenue Over $110 Million
Expected Stock impact: Noticeably Positive
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) announced its financial results for the fourth quarter and full year ended December 31, 2025, showcasing a remarkable 83% increase in product sales compared to the same quarter in the previous year. The company reported Q4 2025 product sales of $21.3 million, driven by strong performances from key products including ALKINDI SPRINKLE and the newly launched DESMODA, the first FDA-approved desmopressin oral solution. Eton's basic GAAP earnings per share (EPS) for the fourth quarter was $0.06, with a fully diluted GAAP EPS of $0.05. On a non-GAAP basis, the company reported a basic EPS of $0.21 and a fully diluted EPS of $0.19, alongside an Adjusted EBITDA of $6.2 million, marking a 195% increase from the prior year.
The company also announced its expectations for 2026, projecting revenues to exceed $110 million with an Adjusted EBITDA margin of over 30%. This optimistic outlook is bolstered by the recent acquisition of HEMANGEOL, which is anticipated to be accretive to earnings in 2026. Eton's CEO, Sean Brynjelsen, expressed confidence in the company's growth trajectory, highlighting the successful launch of three major products in 2025 and the strong reception of DESMODA in its initial weeks on the market. The company plans to hold a conference call to discuss these results and future strategies, further engaging with investors and stakeholders.
The company also announced its expectations for 2026, projecting revenues to exceed $110 million with an Adjusted EBITDA margin of over 30%. This optimistic outlook is bolstered by the recent acquisition of HEMANGEOL, which is anticipated to be accretive to earnings in 2026. Eton's CEO, Sean Brynjelsen, expressed confidence in the company's growth trajectory, highlighting the successful launch of three major products in 2025 and the strong reception of DESMODA in its initial weeks on the market. The company plans to hold a conference call to discuss these results and future strategies, further engaging with investors and stakeholders.
